

Offer **HOPE** to your advanced heart failure patients

If patients have **1 or more** risk factors...



John

Implanted in 2013 at age 79

H	Hospitalizations	≥ 1 in the last 6 months
O	Optimal medical management ineffective	Intolerance to neurohormonal antagonists such as ARBs, BBs, and ACE inhibitors; not responsive to increasing diuretics or CRT therapy
P	Physical activity limited	Inability to walk 1 block without shortness of breath
E	Ejection fraction	< 30%

...it's time for a HeartMate II® consultation

HeartMate II offers:

- Survival advantage 7 times greater than medical management alone¹
- 81% of patients return to NYHA Class I or Class II within 6 months²

Refer earlier for better outcomes³

	INTERMACS advanced heart failure profiles ⁴ Prognostic guide for HeartMate II consultation	Time frame for intervention ⁵	
AHA Stage C NYHA Class III ⁴	7 Advanced NYHA III symptoms <i>Living comfortably with limited physical activity</i>	Months	
	6 Exertion limited <i>Walking wounded</i>		
AHA Stage D NYHA Class IV ⁴	5 Exertion intolerant <i>Housebound</i>		Weeks
	4 Resting symptoms <i>Frequent flyer</i>		
	3 Inotrope dependent <i>Dependent stability</i>		
	2 Progressive decline on inotropic support <i>Sliding on inotropes</i>		Hours
	1 Critical cardiogenic shock <i>Crash and burn</i>		

Early intervention with HeartMate II leads to³:

1.9 times higher survival rate at 3 years

Profile **4 - 7** 96% 3-year survival rate
Profile **1** 51% 3-year survival rate

27-day reduction in length of stay

Profile **4 - 7** 17 days
Profile **1** 44 days

HeartMate II[®]
Left Ventricular Assist System

www.HeartMatePro.com



References: 1. Park SJ, Milano CA, Tatroles AJ, et al; for the HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. *Circ Heart Fail.* 2012;5(2):241-248.

2. Rose EA, Gelijns AC, Moskowitz AJ, et al; for the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med.* 2001;345(20):1435-1443. 3. Boyle AJ, Ascheim DD, Russo MJ, et al. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. *J Heart Lung Transplant.* 2011;30(4):402-407. 4. Stewart GC, Stevenson LW. Keeping left ventricular assist device acceleration on track. *Circulation.* 2011;123(14):1559-1568. 5. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. *J Heart Lung Transplant.* 2009;28(6):535-541.

Thoratec Corporation, 6035 Stoneridge Drive, Pleasanton, CA 94588
1-925-847-8600 1-800-528-2577 www.thoratec.com
Thoratec, HeartMate II, and the Thoratec logo are registered trademarks of Thoratec Corporation.
©2014 Thoratec Corporation. All rights reserved. US-HM2-11140123